Add like
Add dislike
Add to saved papers

Prevalence of obesity and metabolic syndrome in Taiwan.

BACKGROUND/PURPOSE: Obesity and metabolic syndrome (MS) are major risk factors for the development of type 2 diabetes and cardiovascular diseases (CVD). This study estimated the prevalence of obesity and MS in Taiwan.

METHODS: Data from a nationwide cross-sectional population-based survey of 5936 participants (2815 men, 3121 women; age range, 20-79.9 years) in 2002 were analyzed. Obesity was defined as a body mass index (BMI) > or = 27 kg/m(2) according to the criteria of the Department of Health in Taiwan. The prevalence of MS was estimated using the definitions of the modified Adult Treatment Panel III (ATP III), the International Diabetes Federation for Chinese (MS-IDF(C)) and the MS criteria for Taiwanese (MS-TW).

RESULTS: The overall prevalence of obesity in men was significantly greater than in women (19.2% vs. 13.4%, p < 0.0001). The age-standardized prevalence of MS was 15.7% by the modified ATP III criteria, 14.3% by the MS-IDF(C) criteria and 16.4% by the MS-TW criteria. The prevalence of obesity and MS significantly increased with age (trend test, p < 0.0001) in men and women. The risk of MS and its components increased significantly with BMI, and showed a marked increase with BMI > or = 24 kg/m(2). MS as classified by the MS-IDF(C) criteria failed to identify subjects at high risk of CVD who did not have abdominal obesity, including those with hypertension, type 2 diabetes and dyslipidemia.

CONCLUSION: This study found a high prevalence of obesity and MS in Taiwan. The definitions of MS by the modified ATP III and MS-TW criteria were better able to detect high CVD risk than the MS-IDF(C) criteria.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app